These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8154521)

  • 61. Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group.
    Weir MR; Berger ML; Weeks ML; Liss CL; Santanello NC
    Am J Cardiol; 1996 Mar; 77(7):475-9. PubMed ID: 8629587
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
    Golay A; Lehmann T; James R; Pometta D
    Schweiz Med Wochenschr; 1993 Aug; 123(33):1553-8. PubMed ID: 8372340
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia.
    Cutler N; Sramek J; Veroff A; Block G; Stauffer L; Lines C
    Br J Clin Pharmacol; 1995 Mar; 39(3):333-6. PubMed ID: 7619678
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias.
    Glueck CJ; Speirs J; Tracy T
    J Lab Clin Med; 1990 May; 115(5):603-9. PubMed ID: 2341762
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
    Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise.
    Reust CS; Curry SC; Guidry JR
    West J Med; 1991 Feb; 154(2):198-200. PubMed ID: 2006566
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.
    Kyrklund C; Backman JT; Kivistö KT; Neuvonen M; Laitila J; Neuvonen PJ
    Clin Pharmacol Ther; 2001 May; 69(5):340-5. PubMed ID: 11372002
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Statin-induced Parkinson's-syndrome. Reader's letter on the article by J. Finsterer in "Der Nervenarzt" (2003) 74:115-122].
    Müller T
    Nervenarzt; 2003 Aug; 74(8):726-7. PubMed ID: 12904874
    [No Abstract]   [Full Text] [Related]  

  • 72. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
    Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F
    Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors.
    Ballarè M; Campanini M; Airoldi G; Zaccala G; Bertoncelli MC; Cornaglia G; Porzio M; Monteverde A
    Minerva Gastroenterol Dietol; 1992; 38(1):41-4. PubMed ID: 1520752
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
    Schmidt J; Schmitt C; Hockwin O
    Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?
    Weismantel D; Danis P
    J Fam Pract; 2001 Nov; 50(11):927-8. PubMed ID: 11711005
    [No Abstract]   [Full Text] [Related]  

  • 76. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
    Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
    J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
    Liebhaber MI; Wright RS; Gelberg HJ; Dyer Z; Kupperman JL
    Chest; 1999 Mar; 115(3):886-9. PubMed ID: 10084510
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pravastatin-associated inflammatory myopathy.
    Schalke BB; Schmidt B; Toyka K; Hartung HP
    N Engl J Med; 1992 Aug; 327(9):649-50. PubMed ID: 1640970
    [No Abstract]   [Full Text] [Related]  

  • 79. Parkinsonism unmasked by lovastatin.
    Müller T; Kuhn W; Pöhlau D; Przuntek H
    Ann Neurol; 1995 May; 37(5):685-6. PubMed ID: 7755369
    [No Abstract]   [Full Text] [Related]  

  • 80. Lovastatin and myopathy.
    Tobert JA
    Am J Med; 1994 Mar; 96(3):300-1. PubMed ID: 8154521
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.